In vivo, blocking CXCR2 inhibits neutrophil mobilization, and the combination of CCR inhibitors and CXCR2 inhibitors enhances the pancreatic cancer response to FOLFIRINOX chemotherapy (83). Here, CXCR2 is linked to pancreatic neoplasm.